Judith A Ripperger, PAC Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 824 Huntington Ave, Warren, IN 46792 Phone: 260-375-2965 Fax: 260-375-2969 |
Tamara K Troutt, PA Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 470 Bennett Dr, Warren, IN 46792 Phone: 260-375-3670 Fax: 260-375-3669 |
News Archive
Researchers at the University of Pittsburgh Schools of the Health Sciences studying links between an early sign of heart disease called coronary artery calcification and body fat have found that, paradoxically, more fat may have some advantages, at least for people particularly women who have type 1 diabetes.
Intellikine, Inc., a company focused on the discovery and development of innovative, small molecule drugs targeting the PI3K/mTOR pathway, announced today that the first patient has been treated in a Phase I dose escalation study of INK1117 in patients with advanced solid malignancies.
GE Healthcare today announced that it has submitted an application to amend its European Marketing Authorisation that will allow the company to manufacture Optison 0.19 mg/ml dispersion for injection within its own facility.
Cebix Incorporated today announced that data from a Phase 1 study demonstrated that Ersatta, the company's long-acting form of C-peptide, was well tolerated with no serious adverse events in patients with type 1 diabetes and exhibited a pharmacokinetic profile consistent with once-weekly dosing.
Recently, a group of researchers analyzed 122 pregnant women and their neonates at the time of birth. All the women studied received 1 or both doses of a messenger RNA (mRNA)-based vaccine for COVID-19. Of the 122 women part of the study, 55 had received only the first dose of the vaccine while 67 women had received both doses of the mRNA vaccine by the time they gave birth; 85 women had received the Pfizer-BioNTech vaccine, and 37 women received the Moderna vaccine. The study is published on the preprint server, bioRxiv.
› Verified 7 days ago